Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Navigation/Suche

• Forscher*innen.
• Institutionen.
• Projekte.
• Publikationen.
• Partner.
• Geldgeber.
• Ausstattung.
• Knowhow.
• Forschungsfelder.

Publikationen

Suchbegriffe: ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS - THERAPEUTIC USE , . Treffer: 290

2021

Beyer, J; Collette, L; Sauvé, N; Daugaard, G; Feldman, DR; Tandstad, T; Tryakin, A; Stahl, O; Gonzalez-Billalabeitia, E; De, Giorgi, U; Culine, S; de, Wit, R; Hansen, AR; Bebek, M; Terbuch, A; Albany, C; Hentrich, M; Gietema, JA; Negaard, H; Huddart, RA; Lorch, A; Cafferty, FH; Heng, DYC; Sweeney, CJ; Winquist, E; Chovanec, M; Fankhauser, C; Stark, D; Grimison, P; Necchi, A; Tran, B; Heidenreich, A; Shamash, J; Sternberg, CN; Vaughn, DJ; Duran, I; Bokemeyer, C; Patrikidou, A; Cathomas, R; Assele, S; Gillessen, S, , International, Germ, Cell, Cancer, Classification, Update, Consortium Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium.
J Clin Oncol. 2021; 39(14):1553-1562 Doi: 10.1200/JCO.20.03292 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Gillessen, S; Sauvé, N; Collette, L; Daugaard, G; de, Wit, R; Albany, C; Tryakin, A; Fizazi, K; Stahl, O; Gietema, JA; De, Giorgi, U; Cafferty, FH; Hansen, AR; Tandstad, T; Huddart, RA; Necchi, A; Sweeney, CJ; Garcia-Del-Muro, X; Heng, DYC; Lorch, A; Chovanec, M; Winquist, E; Grimison, P; Feldman, DR; Terbuch, A; Hentrich, M; Bokemeyer, C; Negaard, H; Fankhauser, C; Shamash, J; Vaughn, DJ; Sternberg, CN; Heidenreich, A; Beyer, J, , International, Germ, Cell, Cancer, Classification, Update, Consortium Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium.
J Clin Oncol. 2021; 39(14):1563-1574 Doi: 10.1200/JCO.20.03296 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Reitsamer, R; Peintinger, F; Forsthuber, E; Sir, A The applicability of Magseed® for targeted axillary dissection in breast cancer patients treated with neoadjuvant chemotherapy.
Breast. 2021; 57:113-117 Doi: 10.1016/j.breast.2021.03.008 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2020

Dubsky, PC; Singer, CF; Egle, D; Wette, V; Petru, E; Balic, M; Pichler, A; Greil, R; Petzer, AL; Bago-Horvath, Z; Fesl, C; Meek, SM; Kronenwett, R; Rudas, M; Gnant, M; Filipits, M; Austrian Breast and Colorectal Cancer Study Group The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial.
Eur J Cancer. 2020; 134:99-106 Doi: 10.1016/j.ejca.2020.04.020 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Hecht, M; Gostian, AO; Eckstein, M; Rutzner, S; von, der, Grün, J; Illmer, T; Hautmann, MG; Klautke, G; Laban, S; Brunner, T; Hinke, A; Becker, I; Frey, B; Semrau, S; Geppert, CI; Hartmann, A; Balermpas, P; Budach, W; Gaipl, US; Iro, H; Fietkau, R Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8.
J Immunother Cancer. 2020; 8(2): Doi: 10.1136/jitc-2020-001378 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Hurvitz, SA; Martin, M; Press, MF; Chan, D; Fernandez-Abad, M; Petru, E; Rostorfer, R; Guarneri, V; Huang, CS; Barriga, S; Wijayawardana, S; Brahmachary, M; Ebert, PJ; Hossain, A; Liu, J; Abel, A; Aggarwal, A; Jansen, VM; Slamon, DJ Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR⁺/HER2^- Breast Cancer.
CLIN CANCER RES. 2020; 26(3): 566-580. Doi: 10.1158/1078-0432.CCR-19-1425 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Steger, GG; Egle, D; Bartsch, R; Pfeiler, G; Petru, E; Greil, R; Helfgott, R; Marth, C; Öhler, L; Hubalek, M; Lang, A; Tinchon, C; Haslbauer, F; Redl, A; Hock, K; Hennebelle, M; Mraz, B; Gnant, M Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT.
Breast. 2020; 50:64-70 Doi: 10.1016/j.breast.2020.01.035 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2019

Barth, DA; Riedl, JM; Posch, F; Smolle, MA; Kasparek, AK; Niedrist, T; Szkandera, J; Stöger, H; Pichler, M; Stotz, M; Gerger, A Critical evaluation of platelet size as a prognostic biomarker in colorectal cancer across multiple treatment settings: a retrospective cohort study.
Clin Transl Oncol. 2019; 21(8):1034-1043 Doi: 10.1007/s12094-019-02037-7 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Filipits, M; Dubsky, P; Rudas, M; Greil, R; Balic, M; Bago-Horvath, Z; Singer, CF; Hlauschek, D; Brown, K; Bernhisel, R; Kronenwett, R; Lancaster, JM; Fitzal, F; Gnant, M Prediction of Distant Recurrence Using EndoPredict Among Women with ER⁺, HER2^- Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only.
Clin Cancer Res. 2019; 25(13):3865-3872 Doi: 10.1158/1078-0432.CCR-19-0376 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Moik, F; Riedl, JM; Winder, T; Terbuch, A; Rossmann, CH; Szkandera, J; Bauernhofer, T; Kasparek, AK; Schaberl-Moser, R; Reicher, A; Prinz, F; Pichler, M; Stöger, H; Stotz, M; Gerger, A; Posch, F Benefit of second-line systemic chemotherapy for advanced biliary tract cancer: A propensity score analysis.
Sci Rep. 2019; 9(1):5548 Doi: 10.1038/s41598-019-42069-1 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Weide, B; Eigentler, T; Catania, C; Ascierto, PA; Cascinu, S; Becker, JC; Hauschild, A; Romanini, A; Danielli, R; Dummer, R; Trefzer, U; Elia, G; Neri, D; Garbe, C A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients.
Cancer Immunol Immunother. 2019; 68(9):1547-1559 Doi: 10.1007/s00262-019-02383-z
Web of Science PubMed FullText FullText_MUG

 

2018

Gandhi, L; Rodríguez-Abreu, D; Gadgeel, S; Esteban, E; Felip, E; De Angelis, F; Domine, M; Clingan, P; Hochmair, MJ; Powell, SF; Cheng, SY; Bischoff, HG; Peled, N; Grossi, F; Jennens, RR; Reck, M; Hui, R; Garon, EB; Boyer, M; Rubio-Viqueira, B; Novello, S; Kurata, T; Gray, JE; Vida, J; Wei, Z; Yang, J; Raftopoulos, H; Pietanza, MC; Garassino, MC; KEYNOTE-189 Investigators Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
N Engl J Med. 2018; 378(22): 2078-2092. Doi: 10.1056/NEJMoa1801005
Web of Science PubMed FullText FullText_MUG

 

Hann, A; Nosalski, E; Hermann, PC; Egger, J; Seufferlein, T; Keller, F Chemotherapeutic agents eligible for prior dosing in pancreatic cancer patients requiring hemodialysis: a systematic review
.
Clin Nephrol. 2018; 90(2):125-141 Doi: 10.5414/CN109327
Web of Science PubMed FullText FullText_MUG

 

Terbuch, A; Posch, F; Partl, R; Zurl, B; Bauernhofer, T; Pichler, M; Szkandera, J; Hutterer, GC; Pummer, K; Kapp, KS; Stöger, H; Gerger, A; Stotz, M Risk stratification for febrile neutropenia in patients with testicular germ cell tumors.
Cancer Med. 2018; 7(2):508-514 Doi: 10.1002/cam4.1317 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2017

Eisterer, W; Piringer, G; DE Vries, A; Öfner, D; Greil, R; Tschmelitsch, J; Samonigg, H; Sölkner, L; Gnant, M; Thaler, J; Austrian Breast and Colorectal Cancer Study Group Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.
Anticancer Res. 2017; 37(5):2683-2691 Doi: 10.21873/anticanres.11617 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Ferrari, S; Bielack, SS; Smeland, S; Longhi, A; Egerer, G; Sundby Hall, K; Donati, D; Kevric, M; Brosjö, O; Comandone, A; Werner, M; Monge, O; Palmerini, E; Berdel, WE; Bjerkehagen, B; Paioli, A; Lorenzen, S; Eriksson, M; Gambarotti, M; Tunn, PU; Jebsen, NL; Cesari, M; von Kalle, T; Ferraresi, V; Schwarz, R; Bertulli, R; Kasparek, AK; Grignani, G; Krasniqi, F; Sorg, B; Hecker-Nolting, S; Picci, P; Reichardt, P EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma.
Tumori. 2017; 104(1):30-36 Doi: 10.5301/tj.5000696
Web of Science PubMed FullText FullText_MUG

 

Hann, A; Bohle, W; Egger, J; Zoller, W Feasibility of alternating induction and maintenance chemotherapy in pancreatic cancer.
Sci Rep. 2017; 7(3): 41549-41549. Doi: 10.1038/srep41549 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Longhi, A; Bielack, SS; Grimer, R; Whelan, J; Windhager, R; Leithner, A; Gronchi, A; Biau, D; Jutte, P; Krieg, AH; Klenke, FM; Grignani, G; Donati, DM; Capanna, R; Casanova, J; Gerrand, C; Bisogno, G; Hecker-Nolting, S; De Lisa, M; D'Ambrosio, L; Willegger, M; Scoccianti, G; Ferrari, S Extraskeletal osteosarcoma: A European Musculoskeletal Oncology Society study on 266 patients.
Eur J Cancer. 2017; 74(1):9-16 Doi: 10.1016/j.ejca.2016.12.016 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Mairinger, FD; Vollbrecht, C; Flom, E; Christoph, DC; Schmid, KW; Kollmeier, J; Popper, HH; Mairinger, T; Walter, RFH Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma.
Oncotarget. 2017; 8(23):37502-37510 Doi: 10.18632/oncotarget.16398 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Pleyer, L; Döhner, H; Dombret, H; Seymour, JF; Schuh, AC; Beach, CL; Swern, AS; Burgstaller, S; Stauder, R; Girschikofsky, M; Sill, H; Schlick, K; Thaler, J; Halter, B; Machherndl Spandl, S; Zebisch, A; Pichler, A; Pfeilstöcker, M; Autzinger, EM; Lang, A; Geissler, K; Voskova, D; Sperr, WR; Hojas, S; Rogulj, IM; Andel, J; Greil, R Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group.
Int J Mol Sci. 2017; 18(2): Doi: 10.3390/ijms18020415 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Schramm, A; Schochter, F; Friedl, TWP; de Gregorio, N; Andergassen, U; Alunni-Fabbroni, M; Trapp, E; Jaeger, B; Heinrich, G; Camara, O; Decker, T; Ober, A; Mahner, S; Fehm, TN; Pantel, K; Fasching, PA; Schneeweiss, A; Janni, W; Rack, BK; SUCCESS Study Group Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer.
Clin Breast Cancer. 2017; 17(4):279-285 Doi: 10.1016/j.clbc.2016.11.008
Web of Science PubMed FullText FullText_MUG

 

2016

Andreou, D; Werner, M; Pink, D; Traub, F; Schuler, MK; Gosheger, G; Jobke, B; Reichardt, P; Tunn, PU Histological response assessment following neoadjuvant isolated limb perfusion in patients with primary, localised, high-grade soft tissue sarcoma.
Int J Hyperthermia. 2016; 32(2): 159-64. Doi: 10.3109/02656736.2015.1109146
Web of Science PubMed FullText FullText_MUG

 

Bonin, S; Donada, M; Bussolati, G; Nardon, E; Annaratone, L; Pichler, M; Chiaravalli, AM; Capella, C; Hoefler, G; Stanta, G A synonymous EGFR polymorphism predicting responsiveness to anti-EGFR therapy in metastatic colorectal cancer patients.
Tumour Biol. 2016; 37(6):7295-7303 Doi: 10.1007/s13277-015-4543-3
Web of Science PubMed FullText FullText_MUG

 

Hoeppner, J; Lordick, F; Brunner, T; Glatz, T; Bronsert, P; Röthling, N; Schmoor, C; Lorenz, D; Ell, C; Hopt, UT; Siewert, JR ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286).
BMC Cancer. 2016; 16:503 Doi: 10.1186/s12885-016-2564-y [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Rack, B; Jückstock, J; Trapp, E; Weissenbacher, T; Alunni-Fabbroni, M; Schramm, A; Widschwendter, P; Lato, K; Zwingers, T; Lorenz, R; Tesch, H; Schneeweiss, A; Fasching, P; Mahner, S; Beckmann, MW; Lichtenegger, W; Janni, W; SUCCESS Study Group CA27.29 as a tumour marker for risk evaluation and therapy monitoring in primary breast cancer patients.
Tumour Biol. 2016; 37(10):13769-13775 Doi: 10.1007/s13277-016-5171-2
Web of Science PubMed FullText FullText_MUG

 

Schramm, A; Friedl, TW; Schochter, F; Scholz, C; de Gregorio, N; Huober, J; Rack, B; Trapp, E; Alunni-Fabbroni, M; Müller, V; Schneeweiss, A; Pantel, K; Meier-Stiegen, F; Hartkopf, A; Taran, FA; Wallwiener, D; Janni, W; Fehm, T Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program.
Arch Gynecol Obstet. 2016; 293(2):271-281 Doi: 10.1007/s00404-015-3879-7
Web of Science PubMed FullText FullText_MUG

 

von Bueren, AO; Kortmann, RD; von Hoff, K; Friedrich, C; Mynarek, M; Müller, K; Goschzik, T; Zur Mühlen, A; Gerber, N; Warmuth-Metz, M; Soerensen, N; Deinlein, F; Benesch, M; Zwiener, I; Kwiecien, R; Faldum, A; Bode, U; Fleischhack, G; Hovestadt, V; Kool, M; Jones, D; Northcott, P; Kuehl, J; Pfister, S; Pietsch, T; Rutkowski, S Treatment of Children and Adolescents With Metastatic Medulloblastoma and Prognostic Relevance of Clinical and Biologic Parameters.
J Clin Oncol. 2016; 34(34):4151-4160 Doi: 10.1200/JCO.2016.67.2428
Web of Science PubMed FullText FullText_MUG

 

2015

Benesch, M; Lackner, H; Pilhatsch, A; Gürtl-Lackner, B; Schwinger, W; Urban, C Long-term Remission in a Female With Multiple Relapsed Juvenile Granulosa Cell Tumor.
J Pediatr Hematol Oncol. 2015; 37(8):e486-e489 Doi: 10.1097/MPH.0000000000000387 (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

Bossuyt, V; Provenzano, E; Symmans, WF; Boughey, JC; Coles, C; Curigliano, G; Dixon, JM; Esserman, LJ; Fastner, G; Kuehn, T; Peintinger, F; von Minckwitz, G; White, J; Yang, W; Badve, S; Denkert, C; MacGrogan, G; Penault-Llorca, F; Viale, G; Cameron, D; Breast International Group-North American Breast Cancer Group (BIG-NABCG) collaboration Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.
ANN ONCOL. 2015; 26(7): 1280-1291. Doi: 10.1093/annonc/mdv161 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Fastner, G; Reitsamer, R; Ziegler, I; Zehentmayr, F; Fussl, C; Kopp, P; Peintinger, F; Greil, R; Fischer, T; Deutschmann, H; Sedlmayer, F IOERT as anticipated tumor bed boost during breast-conserving surgery after neoadjuvant chemotherapy in locally advanced breast cancer--results of a case series after 5-year follow-up.
Int J Cancer. 2015; 136(5): 1193-1201. Doi: 10.1002/ijc.29064 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Fitzal, F; Filipits, M; Rudas, M; Greil, R; Dietze, O; Samonigg, H; Lax, S; Herz, W; Dubsky, P; Bartsch, R; Kronenwett, R; Gnant, M The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial.
Br J Cancer. 2015; 112(8):1405-1410 Doi: 10.1038/bjc.2015.98 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Gakis, G; Morgan, TM; Daneshmand, S; Keegan, KA; Todenhöfer, T; Mischinger, J; Schubert, T; Zaid, HB; Hrbacek, J; Ali-El-Dein, B; Clayman, RH; Galland, S; Olugbade, K; Rink, M; Fritsche, HM; Burger, M; Chang, SS; Babjuk, M; Thalmann, GN; Stenzl, A; Efstathiou, JA Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: results of the international collaboration on primary urethral carcinoma.
Ann Oncol. 2015; 26(8):1754-1759 Doi: 10.1093/annonc/mdv230 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Gnant, M; Mlineritsch, B; Stoeger, H; Luschin-Ebengreuth, G; Knauer, M; Moik, M; Jakesz, R; Seifert, M; Taucher, S; Bjelic-Radisic, V; Balic, M; Eidtmann, H; Eiermann, W; Steger, G; Kwasny, W; Dubsky, P; Selim, U; Fitzal, F; Hochreiner, G; Wette, V; Sevelda, P; Ploner, F; Bartsch, R; Fesl, C; Greil, R; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.
Ann Oncol. 2015; 26(2):313-320 Doi: 10.1093/annonc/mdu544 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Kaczirek, K; Ciuleanu, TE; Vrbanec, D; Marton, E; Messinger, D; Liegl-Atzwanger, B; Wrba, F; Knittelfelder, R; Lindner, E; Zielinski, CC; Streubel, B; Brodowicz, T FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
Clin Colorectal Cancer. 2015; 14(2):91-98 Doi: 10.1016/j.clcc.2014.12.003
Web of Science PubMed FullText FullText_MUG

 

Lamm, W; Wohlfarth, P; Bojic, M; Schörgenhofer, C; Drach, J; Gisslinger, H; Worel, N; Schiefer, A; Schulenburg, A; Agis, H; Kalhs, P; Greinix, HT; Schellongowski, P; Rabitsch, W Outcome in Multiple Myeloma Patients Eligible for Stem Cell Transplantation: A Single-Center Experience.
Oncology. 2015; 89(4): 196-204. Doi: 10.1159/000437055
Web of Science PubMed FullText FullText_MUG

 

Melchardt, T; Troppan, K; Weiss, L; Hufnagl, C; Neureiter, D; Tränkenschuh, W; Schlick, K; Huemer, F; Deutsch, A; Neumeister, P; Greil, R; Pichler, M; Egle, A Independent Prognostic Value of Serum Markers in Diffuse Large B-Cell Lymphoma in the Era of the NCCN-IPI.
J Natl Compr Canc Netw. 2015; 13(12):1501-1508 Doi: 10.6004/jnccn.2015.0178 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Pircher, M; Mlineritsch, B; Fridrik, MA; Dittrich, C; Lang, A; Petru, E; Weltermann, A; Thaler, J; Hufnagl, C; Gampenrieder, SP; Rinnerthaler, G; Ressler, S; Ulmer, H; Greil, R Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trial.
Anticancer Res. 2015; 35(1):517-521
Web of Science PubMed

 

Troppan, KT; Melchardt, T; Deutsch, A; Schlick, K; Stojakovic, T; Bullock, MD; Reitz, D; Beham-Schmid, C; Weiss, L; Neureiter, D; Wenzl, K; Greil, R; Neumeister, P; Egle, A; Pichler, M The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients.
Eur J Haematol. 2015; 95(6):538-544 Doi: 10.1111/ejh.12529
Web of Science PubMed FullText FullText_MUG

 

Volgger, B; Zeimet, AG; Reinthaller, A; Petru, E; Schauer, C; Klein, M; Sevelda-Schwarzgruber, U; Bogner, G; Wolfram, G; Marth, C Carboplatin and nonpegylated liposomal doxorubicin in primary advanced or recurrent endometrial cancer: a phase 2 trial conducted by AGO Austria.
Int J Gynecol Cancer. 2015; 25(2):257-262 Doi: 10.1097/IGC.0000000000000352 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Zhao, Q; Kretschmer, N; Bauer, R; Efferth, T Shikonin and its derivatives inhibit the epidermal growth factor receptor signaling and synergistically kill glioblastoma cells in combination with erlotinib.
Int J Cancer. 2015; 137(6):1446-1456 Doi: 10.1002/ijc.29483 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2014

Aigner, B; Bauernhofer, T; Petru, E; Niederkorn, A; Arzberger, EJ; Richtig, E Complete recovery of a wide local reaction by the use of dexrazoxane 72 hours after epirubicin extravasation: case report and review of the literature.
Dermatology. 2014; 229(4):288-292 Doi: 10.1159/000365391 (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

Apalla, Z; Lallas, A; Tzellos, T; Sidiropoulos, T; Lefaki, I; Trakatelli, M; Sotiriou, E; Lazaridou, E; Evangelou, G; Patsatsi, A; Kyrgidis, A; Stratigos, A; Zalaudek, I; Argenziano, G; Ioannides, D Applicability of dermoscopy for evaluation of patients' response to nonablative therapies for the treatment of superficial basal cell carcinoma.
Br J Dermatol. 2014; 170(4):809-815 Doi: 10.1111/bjd.12749 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Aurer, I; Bašić-Kinda, S; Radman, I; Ilić, I; Grah, JJ Burkitt lymphomas failing dose-adjusted R-EPOCH (DA-R-EPOCH).
Ann Hematol. 2014; 93(1):177-178 Doi: 10.1007/s00277-013-1771-8 (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

Ediebah, DE; Coens, C; Zikos, E; Quinten, C; Ringash, J; King, MT; Schmucker von Koch, J; Gotay, C; Greimel, E; Flechtner, H; Weis, J; Reeve, BB; Smit, EF; Taphoorn, MJ; Bottomley, A Does change in health-related quality of life score predict survival? Analysis of EORTC 08975 lung cancer trial.
Br J Cancer. 2014; 110(10):2427-2433 Doi: 10.1038/bjc.2014.208 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Eisterer, W; De Vries, A; Öfner, D; Rabl, H; Koplmüller, R; Greil, R; Tschmelitsch, J; Schmid, R; Kapp, K; Lukas, P; Sedlmayer, F; Höfler, G; Gnant, M; Thaler, J; Austrian Breast and Colorectal Cancer Study Group (ABCSG) Preoperative treatment with capecitabine, cetuximab and radiotherapy for primary locally advanced rectal cancer--a phase II clinical trial.
Anticancer Res. 2014; 34(11):6767-6773
Web of Science PubMed FullText

 

Goldinger, SM; Zimmer, L; Schulz, C; Ugurel, S; Hoeller, C; Kaehler, KC; Schadendorf, D; Hassel, JC; Becker, J; Hauschild, A; Dummer, R; Dermatology Cooperative Oncology Group (DeCOG) Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
Eur J Cancer. 2014; 50(2):406-410 Doi: 10.1016/j.ejca.2013.09.014
Web of Science PubMed FullText FullText_MUG

 

Hoeppner, J; Zirlik, K; Brunner, T; Bronsert, P; Kulemann, B; Sick, O; Marjanovic, G; Hopt, UT; Makowiec, F Multimodal treatment of locally advanced esophageal adenocarcinoma: which regimen should we choose? Outcome analysis of perioperative chemotherapy versus neoadjuvant chemoradiation in 105 patients.
J Surg Oncol. 2014; 109(3):287-93 Doi: 10.1002/jso.23498
Web of Science PubMed FullText FullText_MUG

 

Hopfinger, G; Nösslinger, T; Lang, A; Linkesch, W; Melchardt, T; Weiss, L; Egle, A; Greil, R Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial.
Ann Hematol. 2014; 93(3):459-462 Doi: 10.1007/s00277-014-2009-0
Web of Science PubMed FullText FullText_MUG

 

Ludwig, H; Kasparu, H; Leitgeb, C; Rauch, E; Linkesch, W; Zojer, N; Greil, R; Seebacher, A; Pour, L; Weißmann, A; Adam, Z Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.
Blood. 2014; 123(7):985-991 Doi: 10.1182/blood-2013-08-521468 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Mian, M; Wasle, I; Gamerith, G; Mondello, P; Melchardt, T; Jäger, T; Linkesch, W; Fiegl, M R-CHOP versus R-COMP: are they really equally effective?
Clin Oncol (R Coll Radiol). 2014; 26(10):648-652 Doi: 10.1016/j.clon.2014.05.012
Web of Science PubMed FullText FullText_MUG

 

Weitere 50 Treffer anzeigen

↑ Seitenanfang / Navigation

© Med Uni Graz • Impressum